Wang Yishan, Hu Qin, Zhao Haixia, Zeng Lulu, Zhao Zhongwei, Li Xia, Weng Qiaoyou, Yang Yang, Chen Minjiang, Ji Jiansong, Qiu Rongfang
Zhejiang Key Laboratory of Imaging and Interventional Medicine, The Fifth Affliated Hospital of Wenzhou Medical University, Lishui 323000, China.
Cixi Biomedical Research Institute, Wenzhou Medical University, Ningbo 315300, China.
Biomolecules. 2025 Jul 18;15(7):1048. doi: 10.3390/biom15071048.
Plant homeodomain (PHD) finger protein 20-like 1 (PHF20L1) is a novel epigenetic "reader" that specifically recognises histone post-translational modifications (PTMs) via its Tudor and PHD finger domains, thereby regulating chromatin remodelling, DNA damage repair, and oncogene transcriptional activation. This review comprehensively summarises the role of PHF20L1 in various cancers, including breast, ovarian, and colorectal cancers, as well as retinoblastomas, and elucidates its molecular mechanisms of action in cancer pathogenesis. Accumulating evidence indicates that PHF20L1 is upregulated in these malignancies and drives tumour progression by promoting proliferation, metastasis, and immune evasion. Furthermore, PHF20L1 orchestrates tumour-related gene expression by interacting with key epigenetic complexes. Given its unique structural features, we propose novel strategies for developing small-molecule inhibitors and combinatorial therapies, providing a theoretical basis for targeted epigenetic regulation for precision treatment. Future research should further investigate the molecular regulatory networks of PHF20L1 in different cancers and other human diseases and focus on developing specific small-molecule inhibitors to enable precision-targeted therapies.
植物同源结构域(PHD)指蛋白20样1(PHF20L1)是一种新型表观遗传“读取器”,它通过其Tudor结构域和PHD指结构域特异性识别组蛋白翻译后修饰(PTM),从而调节染色质重塑、DNA损伤修复和癌基因转录激活。本综述全面总结了PHF20L1在各种癌症中的作用,包括乳腺癌、卵巢癌、结直肠癌以及视网膜母细胞瘤,并阐明了其在癌症发病机制中的分子作用机制。越来越多的证据表明,PHF20L1在这些恶性肿瘤中上调,并通过促进增殖、转移和免疫逃逸来驱动肿瘤进展。此外,PHF20L1通过与关键的表观遗传复合物相互作用来协调肿瘤相关基因的表达。鉴于其独特的结构特征,我们提出了开发小分子抑制剂和联合疗法的新策略,为精准治疗的靶向表观遗传调控提供理论依据。未来的研究应进一步探究PHF20L1在不同癌症和其他人类疾病中的分子调控网络,并专注于开发特异性小分子抑制剂以实现精准靶向治疗。